Sarepta Therapeutics Enters Material Definitive Agreement
Ticker: SRPT · Form: 8-K · Filed: Feb 14, 2025 · CIK: 873303
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
Related Tickers: SRPT
TL;DR
Sarepta inked a new deal, expect financial shifts.
AI Summary
On February 13, 2025, Sarepta Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company is listed under the SIC code 2834 for Pharmaceutical Preparations.
Why It Matters
This filing signals a significant new contract or financial commitment for Sarepta Therapeutics, potentially impacting its financial obligations and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new financial obligations or strategic risks that may not be immediately apparent.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- February 13, 2025 (date) — Date of earliest event reported
- 2834 (other) — Standard Industrial Classification Code
FAQ
What type of material definitive agreement did Sarepta Therapeutics enter into?
The filing indicates the entry into a material definitive agreement but does not specify the exact nature of the agreement.
What is the nature of the direct financial obligation or off-balance sheet arrangement created?
The filing states the creation of such an obligation but does not provide specific details about its terms or amount.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 13, 2025.
What is Sarepta Therapeutics, Inc.'s Standard Industrial Classification (SIC) code?
Sarepta Therapeutics, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's state of incorporation and fiscal year end?
Sarepta Therapeutics, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 865 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2025-02-14 08:38:17
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT NASDAQ Glo
- $600 million — dit Agreement provides for a five-year, $600 million senior secured revolving credit facilit
Filing Documents
- d875089d8k.htm (8-K) — 28KB
- d875089dex101.htm (EX-10.1) — 925KB
- g875089g0214013949167.jpg (GRAPHIC) — 3KB
- 0001193125-25-026683.txt ( ) — 1306KB
- srpt-20250213.xsd (EX-101.SCH) — 3KB
- srpt-20250213_lab.xml (EX-101.LAB) — 17KB
- srpt-20250213_pre.xml (EX-101.PRE) — 11KB
- d875089d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Credit Agreement, dated February 13, 2025, among Sarepta Therapeutics, Inc., Sarepta Therapeutics Investments, Inc., JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: February 14, 2025 By: /s/ Douglas S. Ingram Douglas S. Ingram President and Chief Executive Officer